Researchers from Weill Cornell Medicine have provided the first national estimate of caregivers’ pain and arthritis experiences that can limit their ability to perform necessary tasks while caring for older family members.
A clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found remaining on the anti-obesity drug tirzepatide promoted additional weight loss and preserved improvements in metabolic and cardiovascular health.
An intercampus collaboration that aims to provide digital health care tools to pregnant refugee women, who are at elevated risk for pregnancy complications but often afraid to seek medical care, has been awarded a National Academy of Medicine Catalyst Prize.
A preclinical study by Weill Cornell Medicine investigators shows that a specific human genetic variant of a receptor that stimulates insulin release may help individuals be more resistant to obesity.
New research has shown that ultrasmall Cornell Prime Dots, or C’Dots, which are among the nanocarriers for therapeutics once thought to be viable only by injection, have the potential to be administered orally.
Researchers created a new technique to treat Type 1 diabetes: implanting a device inside a pocket under the skin that can secrete insulin while avoiding the immunosuppression that typically stymies management of the disease.
A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a previously unknown mechanism for insulin regulation in Type 2 diabetes, according to a new study by Weill Cornell Medicine investigators.
An analysis of beeswax in managed honeybee hives in New York finds a wide variety of pesticide, herbicide and fungicide residues, exposing current and future generations of bees to long-term toxicity.